The Effects of Nanomicelles Curcumin on Glycemic Control, Serum Lipid Profile ,Blood Pressure and Anthropometric Measurements in Patients With Metabolic Syndrome
Not Applicable
- Conditions
- Metabolic Syndrome
- Interventions
- Dietary Supplement: placeboDietary Supplement: nanomicielle curcumin
- Registration Number
- NCT03534024
- Lead Sponsor
- National Nutrition and Food Technology Institute
- Brief Summary
Metabolic syndrome is a condition which is recognized by abdominal obesity, dyslipidemia, hyperglycemia, and hypertension. Curcumin has beneficial effects such as antioxidant and anti-inflammatory effects. nanomcielle curcumin will be used in this study because of the low bioavailability , fast metabolism and low absorption of curcumin powder. Therefore, this study is planned to determine the effects of supplementation of nanomicelle curcumin on glycemic control, serum lipid profile ,blood pressure and anthropometric measurements in patients with metabolic syndrome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- 25<body mass index >40
- waist circumference >102 cm in men or >88 cm in women
- Fasting blood glucose >100 mg/dL
- Triglycerides (TG) > 150 mg/dL
- High density lipoprotein cholesterol (HDL-C) <50 in women or <40 in men
- Systolic blood pressure (SBP) >130 mmHg and diastolic blood pressure (DBP) >85mmHg
Exclusion Criteria
- insulin administration for diabetes control
- hypo- or hyperthyroidism,
- renal failure or other chronic diseases
- pregnancy and breastfeeding
- taking weight loss supplements and obeying unusual weight loss plans
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description plecebo placebo - nanomicielle curcumin nanomicielle curcumin -
- Primary Outcome Measures
Name Time Method hemoglobin A1c (HbA1c) 12 weeks serum glucose 12weeks serum insulin 12weeks homeostatic model assessment of insulin resistance(HOMA-IR) 12weeks homeostatic model assessment of beta cell(HOMA-B) 12weeks serum triglyceride (TG) 12 weeks serum total Cholesterol 12 weeks serum LDL-C 12 weeks serum HDL-C 12 weeks systolic blood pressure 12 weeks diastolic blood pressure 12 weeks serum curcumin 12 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Golbon Sohrab
🇮🇷Tehran, National Nutrition And Food Technology Research Institute, Iran, Islamic Republic of